Standard docking approaches used for the prediction of protein-ligand complexes in the drug development process have problems identifying the correct binding mode of large flexible ligands. Herein we show how additional experimental data from NMR experiments can be used to predict the binding mode of a mucin 1 (MUC-1) pentapeptide recognized by the breast-cancer-selective monoclonal antibody SM3. Distance constraints derived from trNOE and saturation transfer difference NMR experiments are combined with the docking approach PLANTS. The resulting complex structures show excellent agreement with the NMR data and with a published X-ray crystal structure. The method was then further tested on two complexes in order to demonstrate its more gener...
A key component to success in structure-based drug design is reliable information on protein-ligand ...
A key component to success in structure-based drug design is reliable information on protein-ligand ...
A key component to success in structure-based drug design is reliable information on protein–ligand ...
Standard docking approaches used for the prediction of protein ligand complexes in the drug developm...
Standard docking approaches used for the prediction of protein ligand complexes in the drug developm...
Structure-based drug design is an integral part of modern day drug discovery and requires detailed s...
Color poster with text, images, and tables.The crystal structure of the mucin monoclonal antibody SM...
Structure-based drug design is routinely used in modern day drug discovery. However, the success of ...
Structure-based drug design is an integral part of modern day drug discovery and requires detailed s...
Structure-based drug design is an integral part of modern day drug discovery and requires detailed s...
Mucin glycoproteins on breast cancer cells carry shortened carbohydrate chains. These partially degl...
Subunit reassociation in mucin 1, a breast cancer tumor marker, is reported as one of the critical f...
T cell receptors (TCRs) are immune proteins that specifically bind to antigenic molecules, which are...
The class I major histocompatibility complex (MHC) is capable of binding peptides derived from intra...
A key component to success in structure-based drug design is reliable information on protein-ligand ...
A key component to success in structure-based drug design is reliable information on protein-ligand ...
A key component to success in structure-based drug design is reliable information on protein-ligand ...
A key component to success in structure-based drug design is reliable information on protein–ligand ...
Standard docking approaches used for the prediction of protein ligand complexes in the drug developm...
Standard docking approaches used for the prediction of protein ligand complexes in the drug developm...
Structure-based drug design is an integral part of modern day drug discovery and requires detailed s...
Color poster with text, images, and tables.The crystal structure of the mucin monoclonal antibody SM...
Structure-based drug design is routinely used in modern day drug discovery. However, the success of ...
Structure-based drug design is an integral part of modern day drug discovery and requires detailed s...
Structure-based drug design is an integral part of modern day drug discovery and requires detailed s...
Mucin glycoproteins on breast cancer cells carry shortened carbohydrate chains. These partially degl...
Subunit reassociation in mucin 1, a breast cancer tumor marker, is reported as one of the critical f...
T cell receptors (TCRs) are immune proteins that specifically bind to antigenic molecules, which are...
The class I major histocompatibility complex (MHC) is capable of binding peptides derived from intra...
A key component to success in structure-based drug design is reliable information on protein-ligand ...
A key component to success in structure-based drug design is reliable information on protein-ligand ...
A key component to success in structure-based drug design is reliable information on protein-ligand ...
A key component to success in structure-based drug design is reliable information on protein–ligand ...